Clinical trial · Observational
Korean Registry of Non-Small Cell Lung Cancer Patients with EGFR Mutation
Multicenter Prospective and Retrospective Cohort Study in Non-small Cell Lung Cancer Patients with EGFR Mutation: Korean EGFR Registry
NCT06247280CI-TRIAL-00083389active not recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Korean Registry of Non-Small Cell Lung Cancer Patients with EGFR mutation to collect and analyze the patient's clinical features, diagnosis, and treatment results.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| NSCLC | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (4)
- measure
- Clinical characteristics of NSCLC patients with EGFR mutation
- timeFrame
- 12months, 18months, 24months, 36months
- description
- Analysis of clinical characteristics and clinical outcomes in NSCLC patients with EGFR mutation
- measure
- Clinical outcome of NSCLS patients with EGFR mutation
- timeFrame
- 12months, 18months, 24months, 36months
- description
- Analysis of clinical characteristics and clinical outcomes in NSCLC patients with EGFR mutation
- measure
- PFS
- timeFrame
- 12months, 18months, 24months, 36months
- description
- PFS underwent palliative therapy according to stages in NSCLC patients with EGFR mutation
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 20 Years
Show eligibility criteria text
Inclusion Criteria: 1. Adults over 20-year-old with Korean nationality 2. A person who voluntarily signed the informed consent form for this study 3. All stage Non small cell lung cancer patients with EGFR mutation or Metastatic or recurred EGFR mutated NSCLC patients started with EGFR TKI treatment from 2021-01-01. Exclusion Criteria: 1. A person who is not confirmed NSCLC histologically or cytologically. 2. A person who doesn't consent to the study. 3. A person who is unable to complete the study judged by the investigator.
References
Publications (0)
Data not yet available
No reference posted for this study.